RE: Results28 Feb 2022 17:28
Liked the ops update.
Wasn’t to sure on the response about outstanding receivables. Seem to be cutting the debtors a lot of slack whilst they absorb the tech. Hope it yields a good long term partnership and future timely revenue!
The no raise statement from Matthew made up for the ‘wishy washy’ bit and literally turned the SP around as he spoke!
I thought it was close but he was very confident that the immunoINSIGHTS revs would cover costs. Even the high admin run rate needed for growth.
Note he referred to existing business so if there was an acquisition that would be different. Well it would imo be great if we could find the right fit and price, preferably in the US …
The last raise was for organic growth (Dortmund) and to be fair they haven’t returned to market for ops cash. So for the cynics something is paying the wage bills!
Then a big lol on R&D costs, ‘well it’s in the price’, ‘customer pays’ or words to that effect. (I guess as it’s bespoke diagnostics). Whoops Matthew …..cough! cough! Adam.
Smart move! Lol!
Anyways I did grab 4500 more and will be back again later. Everything is great bar the SP.
They are generating hard revenue at huge margins. That sets ONC apart from the many other wannabes.
Imo the revs and contracts are not in the price yet and looks like the market won’t believe the numbers until they see them on the P&L. Then it could rerate over a couple days. That’s the MM’s gaining on the way down and on the way up!
As I intimated before the account change make sense. Looking forward to August.
Usual caveats
Trek